1800-272-662
Shopping Cart 0
countryflagAU
Login

Artiva Biotherapeutics, Inc. Common Stock

Healthcare US ARTV

5.955USD
0.24(4.29%)

Last update at 2026-03-10T20:00:00Z

Day Range

5.646.16
LowHigh

52 Week Range

9.6817.31
LowHigh

Fundamentals

  • Previous Close 5.71
  • Market Cap285.89M
  • Volume135224
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-58.57400M
  • Revenue TTM2.60M
  • Revenue Per Share TTM0.48
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.48

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -27.62400M -58.33500M -71.82500M -17.99100M
Minority interest - - - -
Net income -27.69600M -58.38800M -71.82500M -17.99100M
Selling general administrative 13.91M 20.78M 12.86M 4.43M
Selling and marketing expenses - - - -
Gross profit 33.49M 4.93M 2.00M -
Reconciled depreciation 2.27M 1.16M 0.25M 0.07M
Ebit -30.67100M -59.82900M -71.82500M -17.79200M
Ebitda -28.40500M -58.67100M -71.57700M -17.71900M
Depreciation and amortization 2.27M 1.16M 0.25M 0.07M
Non operating income net other - - - -
Operating income -30.67100M -59.82900M -53.27200M -18.27100M
Other operating expenses 64.16M 64.76M 55.27M 18.27M
Interest expense - - 0.00000M 0.20M
Tax provision 0.07M 0.05M - -
Interest income 2.54M 1.29M 0.00000M 0.00200M
Net interest income 2.54M 1.29M 0.00000M -0.19700M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.07M 0.05M -18.55300M 0.68M
Total revenue 33.49M 4.93M 2.00M 0.00000M
Total operating expenses 64.16M 64.76M 55.27M 18.27M
Cost of revenue - - - -
Total other income expense net 3.05M 1.49M -18.55300M 0.28M
Discontinued operations - - - -
Net income from continuing ops -27.69600M -58.38800M -71.82500M -17.99100M
Net income applicable to common shares - - - -
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 105.11M 133.05M 169.93M 29.23M -
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.09M 1.62M 0.90M 0.67M -
Total liab 267.13M 273.75M 258.78M 50.80M -
Total stockholder equity -162.01500M -140.69600M -88.85800M -21.56700M -
Deferred long term liab - - - - -
Other current liab 8.02M 10.15M 10.13M 3.15M -
Common stock - - - - -
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M -
Retained earnings -181.31100M -152.59100M -93.80300M -21.97800M -
Other liab - - - - -
Good will - - - - -
Other assets - 0.00500M - - -
Cash 53.50M 102.53M 160.92M 25.44M -
Cash and equivalents - - - - -
Total current liabilities 12.23M 25.62M 19.30M 5.76M -
Current deferred revenue - 10.89M 7.29M - -
Net debt -36.59200M -83.08300M -159.18200M -23.32600M 3.77M
Short term debt 3.60M 3.49M 0.43M 0.46M -
Short long term debt - - - - -
Short long term debt total 16.91M 19.45M 1.74M 2.12M -
Other stockholder equity 18.99M 11.89M 4.95M 0.41M -
Property plant equipment - - - - -
Total current assets 79.82M 104.67M 162.29M 26.11M -
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments 23.47M 0.00000M - - -
Net receivables 1.76M 0.53M 0.47M 0.00000M -
Long term debt - - - - 5.64M
Inventory - - - - -
Accounts payable 0.61M 1.10M 1.44M 2.15M -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.31M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.65M 0.76M 3.56M 0.73M -
Deferred long term asset charges - - - - -
Non current assets total 25.29M 28.37M 7.64M 3.13M -
Capital lease obligations 16.91M 19.45M 1.74M 2.12M -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -25.97500M -6.29900M -1.72400M -0.28400M
Change to liabilities - - - -
Total cashflows from investing activities - - - -
Net borrowings - - - -
Total cash from financing activities 24.39M -1.26400M 152.75M 37.40M
Change to operating activities - - - -
Net income -28.72000M -58.78800M -71.82500M -17.99100M
Change in cash -49.01400M -58.39200M 135.73M 23.57M
Begin period cash flow 102.78M 161.17M 25.44M 1.87M
End period cash flow 53.76M 102.78M 161.17M 25.44M
Total cash from operating activities -47.43000M -50.82900M -15.30400M -13.54100M
Issuance of capital stock - - 154.61M 34.85M
Depreciation 2.27M 1.16M 0.25M 0.07M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables -0.51000M -0.05700M -0.46800M 0.00000M
Sale purchase of stock -0.01200M -0.00500M - -
Other cashflows from financing activities 24.40M -1.25900M 152.75M 34.18M
Change to netincome - - - -
Capital expenditures 3.26M 6.30M 1.72M 0.28M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital -28.28000M -3.86600M 33.41M 4.36M
Stock based compensation 7.05M 6.58M 4.31M 0.30M
Other non cash items 0.25M - 18.55M -0.27800M
Free cash flow -50.68800M -57.12800M -17.02800M -13.82500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x)
ARTV
Artiva Biotherapeutics, Inc. Common Stock		 0.24 4.29% 5.96 - - 109.91 1.43 59.57
NVO
Novo Nordisk A/S		 0.16 0.41% 38.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.89 0.98% 494.28 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.71 0.48% 775.75 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Artiva Biotherapeutics, Inc. Common Stock

5505 Morehouse Drive, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. Fred Aslan M.D. President, CEO & Director 1975
Dr. Peter Flynn Ph.D. Co-Founder & Strategic Advisor 1974
Ms. Jennifer Kinsbruner Bush Esq., J.D. Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer 1975
Mr. Christopher P. Horan Chief Technical Operations Officer 1967
Ms. Neha Krishnamohan CFO & Executive VP of Corporate Development 1987
Dr. Thorsten Graef M.D., Ph.D. Chief Medical Officer 1976
Dr. Heather Raymon Ph.D. Senior Vice President of Research & Early Development 1964
Mr. Javier Coindreau M.D. Senior VP of Medical Affairs NA
Dr. David Moriarty Ph.D. Senior VP of Clinical Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.